Following its curtain-raising at last fall’s meeting of the Radiological Society of North America, GE HealthCare has obtained ...

Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnim | Shionogi has ...

When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...

Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...